Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07198100Recruiting
Ear stimulation, motivation, and insulin sensitivity in depression
This study explores how a gentle electrical stimulation of the ear might affect mood, motivation, and insulin sensitivity in people with and without depression. It aims to see if this non-invasive technique could offer new ways to help with depression.
BonnAges 18–60 - NCT07184502RecruitingPhase 1
Testing a new injection for weight loss in healthy and overweight adults
This trial tests an investigational injection called ZT003 to see if it is safe and how the body processes it. It is for healthy volunteers or those who are overweight or obese, to help understand how this treatment might work.
Brisbane, QueenslandAges 18–65 - NCT07190222RecruitingPhase 3
New medicine for COPD with frequent flare-ups
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
Birmingham, AlabamaAges 40–80 - NCT07185880RecruitingPhase 1/Phase 2
Testing MT-125 for newly diagnosed glioblastoma
This trial tests a new drug called MT-125 for people with a specific type of brain cancer called glioblastoma (GBM) that is IDH wildtype and MGMT unmethylated. The study will see if MT-125 is safe and tolerable, and how well it works.
Phoenix, ArizonaAges 18 years+ - NCT07190209RecruitingPhase 3
Testing lunsekimig for COPD with frequent flare-ups
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
Chandler, ArizonaAges 40–80 - NCT07185815RecruitingPhase 1/Phase 2
Study of a long-acting cariprazine shot for mood and schizophrenia
This trial tests a monthly injection of cariprazine (a medication for mental health conditions) in people who could benefit from it. It aims to see if the shot is safe, tolerable, and effective compared to taking pills every day.
AhmedabadAges 18–64 - NCT07185256RecruitingPhase 1/Phase 2
Gene therapy for Best disease retinal trial
This trial tests a gene therapy called OPGx-BEST1 injected under the retina to treat vision loss from Best vitelliform macular dystrophy or a related condition. It may help people with advanced disease who have a specific genetic change in the BEST1 gene.
Los Angeles, CaliforniaAges 18 years+ - NCT06944457RecruitingPhase 1
Safety Study of MPD-1 for Advanced Solid Tumors
This trial tests a new drug called MPD-1 for people with advanced solid tumors that have not responded to standard treatments. It focuses on patients with specific genetic changes (KRAS mutation or PTEN loss) to see if the drug is safe and how the body processes it.
SeoulAges 19–75 - NCT06942572RecruitingPhase 1/Phase 2
Gene therapy trial for Stargardt disease
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
Aurora, ColoradoAges 12–65 - NCT07182656RecruitingPhase 1
Safety of CIGB-814 in healthy Chinese volunteers
This is a first-in-human study in China testing a new drug called CIGB-814 in healthy volunteers. The goal is to check how safe the drug is, how well it is tolerated, and how the body processes it.
Beijing, Beijing MunicipalityAges 18–45 - NCT07179640RecruitingPhase 1/Phase 2
Testing ALE1 for hypophosphatasia in healthy people and patients
This trial tests a new medicine called ALE1 for hypophosphatasia (HPP), a rare bone condition. It first checks safety in healthy volunteers, then tests if the medicine helps people with HPP.
WürzburgAges 18–50 - NCT06864546Recruiting
Diabetes glucose tracking study for people not on insulin
This study tests a new way to help people with type 2 diabetes track their blood sugar in everyday life. It aims to see if a simple, patient-friendly approach can improve glucose control without needing insulin.
Pavia, PaviaAges 40–70 - NCT07169318RecruitingPhase 1
Safety study of VNT-101 in healthy adults
This first-in-human study tests the safety of a new medicine called VNT-101. Healthy adults aged 18 to 59 who do not smoke and have no major health problems may be able to join. The goal is to see how the body handles the drug and if it is safe.
Overland Park, KansasAges 18–59 - NCT07171983RecruitingPhase 1
Testing a new drug for rheumatoid arthritis
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
Hyderabad, Andhra PradeshAges 18–65 - NCT07169591Recruiting
How birth control affects blood sugar after meals
This study looks at how your body handles blood sugar after a meal if you use a specific type of birth control (certain birth control pills or IUDs) or no hormonal birth control. It may help researchers understand how hormones affect energy and sugar levels.
Hamilton, OntarioAges 18–45 - NCT04611113Recruiting
Nutrition support to help tolerance of cancer chemoradiotherapy
This trial studies whether adding special nutrition support (“immunonutrition”) can help people with head-and-neck cancer tolerate treatment with chemoradiotherapy, and possibly improve comfort and treatment completion. You may be eligible if you are starting or will have curative or extra (adjuvant) chemoradiotherapy and can complete study measurements.
PaviaAges 18 years+ - NCT07155252Recruiting
Home glucose test for type 1 diabetes screening
This study looks at whether you can do an oral glucose tolerance test at home instead of at a clinic. It is for people who have certain antibodies linked to type 1 diabetes or who were recently diagnosed with type 1 diabetes.
New Haven, ConnecticutAges 8–45 - NCT07156201RecruitingPhase 1
Safety study of oral ABS-1230 in healthy adults
This trial tests a new oral medication called ABS-1230 in healthy people to see how safe it is and how the body processes it. You would take either the drug or a placebo (no active ingredient) and be monitored closely.
Sydney, New South WalesAges 18–55 - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT07161700Enrolling by invitationPhase 2
Long-term safety study of SPT-300 for major depression
This study is for people who finished the earlier BUOY-1 study of SPT-300 and want to continue treatment. It tests the long-term safety and tolerability of SPT-300 for major depressive disorder, with or without anxious distress.
Chino, CaliforniaAges 18–66 - NCT07148128RecruitingPhase 1/Phase 2
Testing the safety of WEF-001 for KRAS-mutant cancers
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Dallas, TexasAges 18 years+ - NCT07149831RecruitingPhase 1
Safety study of a diagnostic injection in healthy Chinese adults
This trial tests a new imaging agent called flotufolastat F-18 in healthy volunteers to see how it travels through the body and how safe it is. The results will help doctors use this agent for imaging in future patients.
Beijing, Beijing MunicipalityAges 18–60 - NCT07149454Enrolling by invitationPhase 1
Testing a new antibody to prevent tetanus
This trial tests a new medicine made from antibodies that target tetanus toxin. It may help protect people from tetanus without needing a vaccine.
Lanzhou, GansuAges 18–60 - NCT06732180RecruitingPhase 1
Testing a new drug (GT-02287) for Parkinson's disease
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Darlinghurst, New South WalesAges 30–85
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.